Skip to main content
PHYSIOMICS PLC logo

PHYSIOMICS PLC — Investor Relations & Filings

Ticker · PYC ISIN · GB00BDR6W943 LEI · 213800A71DSZ6ABMTQ91 IL Professional, scientific and technical activities
Open in API
Filings indexed 332 across all filing types
Latest filing 2021-03-12 Report Publication Anno…
Country GB United Kingdom
Listing IL PYC

About PHYSIOMICS PLC

https://www.physiomics.co.uk/

Physiomics PLC is a data-driven consultancy that provides Model-Informed Drug Development (MIDD) services to pharmaceutical and biotechnology companies. The company specializes in accelerating and de-risking the development of new drugs by integrating expertise in Modelling & Simulation, Biostatistics, and Data Science. By applying quantitative pharmacology and pharmacokinetic/pharmacodynamic (PK/PD) modelling, Physiomics supports clients in making smarter, data-driven decisions throughout the drug development pipeline, from preclinical discovery to clinical trials. The company has a notable focus on oncology, leveraging advanced computational biology platforms to optimize treatment strategies and predict patient outcomes.

Recent filings

Filing Released Lang Actions
Presentation and Q&A on Company's Interim Results
Report Publication Announcement Classification · 1% confidence The document is an RNS announcement (RNS Number : 0149S) dated March 12, 2021. The subject is 'Presentation and Q&A on Company's Interim Results' for the six months ended December 31, 2020. It explicitly states that a presentation was made yesterday and provides links to the slide deck (Investor Presentation material) and a recording of the presentation and subsequent Q&A (Call Transcript material). Since the document itself is a short announcement providing links to the presentation slides and the Q&A recording, it fits the definition of a Report Publication Announcement (RPA) or potentially an Investor Presentation (IP) if the focus was solely on the slides. However, because it announces *both* the presentation materials (IP) and the Q&A recording (CT), and it is structured as a brief regulatory notification pointing to external content, RPA is a strong candidate. Given the content explicitly mentions the presentation materials (slide deck) and the Q&A recording, and the document is short (3511 chars), it is primarily an announcement about the publication of these materials. The closest fit that covers the announcement of presentation/call materials is RPA, although IP or CT are also highly relevant to the linked content. Since it announces the availability of the presentation materials, IP is also very strong. Let's re-evaluate based on the definitions: It announces the presentation materials (IP) and the Q&A (CT). If the document was just the slides, it would be IP. If it was just the transcript, it would be CT. Since it announces both and is a short notice, RPA (Report Publication Announcement) is appropriate as it announces the publication of these investor-facing materials. However, the content strongly points to the materials themselves being an Investor Presentation (IP) and a Call Transcript (CT). Given the explicit mention of the 'slide deck' and the 'recording of the presentation, together with the subsequent Q&A', this is a direct announcement of investor presentation materials. IP (Investor Presentation) is the most specific category for the slide deck, which is the primary linked document. I will classify it as IP because the core content being distributed is the presentation slide deck.
2021-03-12 English
Interim Results Presentation
Report Publication Announcement Classification · 1% confidence The document is a regulatory announcement (RNS Number: 0928R) from Physiomics PLC, dated March 4, 2021. The core content announces that the CEO will provide a live presentation relating to the company's 'Interim Results for the six-month period ended 31 December 2020' via the Investor Meet Company platform. This is not the full Interim Report (IR) itself, nor is it the presentation document (IP). Instead, it is an announcement about the upcoming presentation of those results. Since the document is short and its primary function is to announce the timing and logistics of a future event where results will be discussed, it fits best under Report Publication Announcement (RPA) or potentially a general Regulatory Filing (RNS). Given the specific nature of announcing a presentation related to results, RPA is a strong candidate, but since the content is primarily an announcement of an event rather than the publication of a formal report document, and it uses the RNS distribution system, classifying it as a general Regulatory Filing (RNS) is appropriate as a fallback for announcements that don't fit the specific report types, although RPA is also plausible if the focus is strictly on the announcement of the presentation itself. However, the document explicitly mentions 'Interim Results Presentation' and provides details for attending the presentation, which is a form of investor communication. Given the options, and recognizing this is a standard RNS announcement format, RNS is the safest general classification, but since it is announcing a presentation related to interim results, it is very close to an Investor Presentation (IP) announcement. Let's re-evaluate based on the definitions. It announces a presentation about interim results. If the presentation slides were attached, it would be IP. Since it's just the announcement of the event, it's a regulatory announcement (RNS). If we consider the 'Interim Results' context, it's related to the IR, but it's not the IR. It is an announcement of an event. RNS is the most general fit for an RNS-distributed announcement that isn't a specific report type.
2021-03-04 English
Issue of Options
Remuneration Information Classification · 1% confidence The document is clearly identified as an RNS announcement (RNS Number : 8595Q) from Physiomics PLC dated 02 March 2021. The primary content details the 'Issue of Options' to directors and employees, which relates to share schemes and executive compensation/incentives. Crucially, the document concludes with a section titled 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM' detailing transactions by the CEO, COO, and Chairman. This structure—announcing an internal corporate action (option grant) followed by mandatory disclosure of insider transactions—is characteristic of regulatory filings concerning insider dealings or significant corporate events. While it involves directors' transactions, the core purpose is the announcement of the option grant itself, which affects capital structure and management incentives. However, the detailed tables explicitly report transactions by Persons Discharging Managerial Responsibilities (PDMRs) regarding their holdings/options. This strongly aligns with the scope of Director's Dealing (DIRS) or a general Regulatory Filing (RNS). Since the document explicitly details personal share transactions (options granted) by directors (CEO, COO, Chairman), the most specific classification is Director's Dealing (DIRS). If it were purely about remuneration policy, DEF 14A might apply, but this is a specific transaction disclosure. Given the RNS header and the detailed PDMR transaction tables, DIRS is the best fit, with RNS as a strong secondary option if DIRS were not available for option grants.
2021-03-02 English
Interim Results
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Results Statement' for the six-month period ended 31 December 2020. It contains comprehensive financial statements, including the Statement of Comprehensive Income, Statement of Financial Position, and Statement of Changes in Equity, along with management commentary. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). H1 2020
2021-03-01 English
ValiRx Agreement
M&A Activity Classification · 1% confidence The document begins with 'RNS Number : 0102P' and concludes with information about RNS, the news service of the London Stock Exchange, stating that RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider. The content itself is an announcement regarding a new agreement between Physiomics plc and ValiRx plc concerning drug development modeling. This structure and source identification strongly indicate a regulatory news service announcement. Since the content is a specific business update (a new agreement/collaboration) that doesn't fit perfectly into categories like ER, 10-K, or DIV, the most appropriate classification is the general regulatory announcement category, RNS.
2021-02-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to the 'Identity of the issuer', 'Reason for the notification' (specifically 'An acquisition or disposal of voting rights'), and 'Total positions of person(s) subject to the notification obligation', detailing percentage changes in voting rights (e.g., from 5.12% to 6.37%). This structure is characteristic of regulatory filings concerning changes in significant share ownership. The RNS Number and reference to the FCA confirm its regulatory nature. This directly matches the definition for Major Shareholding Notification (MRQ).
2020-12-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.